Clinical Pharmacokinetics of Sulindac. A Dynamic Old Drug

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 1997 Jun 1

PMID 9195115

Citations 26

Authors

N M Davies

M S Watson

Affiliations

Soon will be listed here.

Abstract

Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the indene acetic acid class. The absorption of sulindac is rapid when given orally. Sulindac is reversibly metabolised to sulindac sulphide which has anti-inflammatory and analgesic properties and is irreversibly metabolised to sulindac sulphone which has been suggested to possess antiproliferative effects against tumours. Sulindac and its sulphide and sulphone metabolites bind extensively to plasma albumin. Sulindac is eliminated following bio-transformation; sulindac and sulindac sulphone and their respective glucurooconjugated metabolites are excreted in urine; however only a small amount of the sulindac sulphide metabolite is eliminated in urine. Following long term twice daily administration both sulindac and its metabolites accumulate in plasma. Both patients with cirrhosis and the elderly demonstrate elevated concentrations of all species upon long term sulindac administration as compared with a single dose. The disposition of sulindac and its metabolites may be tied to renal function. In end-stage renal disease, increased free fractions of all species and accumulation of the sulphide and sulphone metabolites, and to a lesser extent sulindac, occurs. Significant drug interactions have been demonstrated for dimethylsulphoxide, cyclosporin, furosemide (frusemide), hydrochlorothiazide, methotrexate and cholestyramine.

Citing Articles

Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer.

Hossain F, Ucar D, Monticone G, Ran Y, Majumder S, Larter K Front Immunol. 2023; 14:1244159.

PMID: 37901240 PMC: 10612326. DOI: 10.3389/fimmu.2023.1244159.

The effect of sulindac on redox homeostasis and apoptosis-related proteins in melanotic and amelanotic cells.

Milinski M, Stas M, Rok J, Beberok A, Wrzesniok D Pharmacol Rep. 2023; 75(4):995-1004.

PMID: 37195561 PMC: 10374796. DOI: 10.1007/s43440-023-00493-1.

Enhanced NSAIDs Solubility in Drug-Drug Formulations with Ciprofloxacin.

Acebedo-Martinez F, Dominguez-Martin A, Alarcon-Payer C, Sevillano-Paez A, Verdugo-Escamilla C, Gonzalez-Perez J Int J Mol Sci. 2023; 24(4).

PMID: 36834716 PMC: 9964002. DOI: 10.3390/ijms24043305.

A critical review on modulators of Multidrug Resistance Protein 1 in cancer cells.

Poku V, Iram S PeerJ. 2022; 10:e12594.

PMID: 35036084 PMC: 8742536. DOI: 10.7717/peerj.12594.

Sulfur-containing therapeutics in the treatment of Alzheimer's disease.

Zhu H, Dronamraju V, Xie W, More S Med Chem Res. 2021; 30(2):305-352.

PMID: 33613018 PMC: 7889054. DOI: 10.1007/s00044-020-02687-1.

References

Levine M, Rothstein R, Laufer I . Giant esophageal ulcer due to Clinoril. AJR Am J Roentgenol. 1991; 156(5):955-6. DOI: 10.2214/ajr.156.5.2017958. View

Ciabattoni G, Cinotti G, Pierucci A, Simonetti B, Manzi M, Pugliese F . Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. N Engl J Med. 1984; 310(5):279-83. DOI: 10.1056/NEJM198402023100502. View

Mistry C, Lote C, Currie W, Vandenburg M, Mallick N . Effects of sulindac on renal function and prostaglandin synthesis in patients with moderate chronic renal insufficiency. Clin Sci (Lond). 1986; 70(5):501-5. DOI: 10.1042/cs0700501. View

Grgurinovich N . High-performance liquid chromatography of sulindac and its sulphone and sulphide metabolites in plasma. J Chromatogr. 1987; 414(1):211-6. DOI: 10.1016/0378-4347(87)80043-9. View

Reinstein L, Mahon Jr R, Russo G . Peripheral neuropathy after concomitant dimethyl sulfoxide use and sulindac therapy. Arch Phys Med Rehabil. 1982; 63(11):581-4. View

Walker R, Gruber V, Rosenberg A, WOLF F, Vandenheuvel W . Computerized mass spectrometric assay for sulindac and its metabolites in human plasma. Anal Biochem. 1979; 95(2):579-86. DOI: 10.1016/0003-2697(79)90776-0. View

Ballas Z, Donta S . Sulindac-induced aseptic meningitis. Arch Intern Med. 1982; 142(1):165-6. View

Koopmans P, Kateman W, Tan Y, van Ginneken C, Gribnau F . Effects of indomethacin and sulindac on hydrochlorothiazide kinetics. Clin Pharmacol Ther. 1985; 37(6):625-8. DOI: 10.1038/clpt.1985.100. View

Russeva V, Stavreva N, Rakovska R, Michailova D . Binding of sulindac to human serum albumin studied by circular dichroism. Arzneimittelforschung. 1994; 44(2):159-62. View

10.

Ripley E, Gehr T, Wallace H, Wade J, Kish C, Sica D . The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone. Int J Clin Pharmacol Ther. 1994; 32(1):12-8. View

11.

Koopmans P, Thien T, Gribnau F . The influence of ibuprofen, diclofenac and sulindac on the blood pressure lowering effect of hydrochlorothiazide. Eur J Clin Pharmacol. 1987; 31(5):553-7. DOI: 10.1007/BF00606629. View

12.

Stubbs R, Ng L, Entwistle L, Bayne W . Analysis of sulindac and metabolites in plasma and urine by high-performance liquid chromatography. J Chromatogr. 1987; 413:171-80. DOI: 10.1016/0378-4347(87)80224-4. View

13.

Dujovne C, Pitterman A, Vincek W, Dobrinska M, Davies R, DUGGAN D . Enterohepatic circulation of sulindac and metabolites. Clin Pharmacol Ther. 1983; 33(2):172-7. DOI: 10.1038/clpt.1983.26. View

14.

Sesin G, OKeefe E, Roberto P . Sulindac-induced elevation of serum cyclosporine concentration. Clin Pharm. 1989; 8(6):445-6. View

15.

Daskalopoulos G, Kronborg I, Katkov W, Gonzalez M, Laffi G, Zipser R . Sulindac and indomethacin suppress the diuretic action of furosemide in patients with cirrhosis and ascites: evidence that sulindac affects renal prostaglandins. Am J Kidney Dis. 1985; 6(4):217-21. DOI: 10.1016/s0272-6386(85)80176-1. View

16.

Minsker D, Jordan P, Kling P, Welch T . The effect of sulindac and sulindac metabolites on arachidonate-induced lethality in rabbits: effect on human, guinea pig, dog, and rat platelet activity. Thromb Res. 1977; 11(2):217-26. DOI: 10.1016/0049-3848(77)90040-8. View

17.

Dunn M, Scharschmidt L, Zambraski E . Mechanisms of the nephrotoxicity of non-steroidal anti-inflammatory drugs. Arch Toxicol Suppl. 1984; 7:328-37. DOI: 10.1007/978-3-642-69132-4_56. View

18.

Takeuchi K, Abe K, Yasujima M, Sato M, Tanno M, Sato K . No adverse effect of non-steroidal anti-inflammatory drugs, sulindac and diclofenac sodium, on blood pressure control with a calcium antagonist, nifedipine, in elderly hypertensive patients. Tohoku J Exp Med. 1991; 165(3):201-8. DOI: 10.1620/tjem.165.201. View

19.

Johnson Jr F, HAMILTON H, Liesch M . Immune hemolytic anemia associated with sulindac. Arch Intern Med. 1985; 145(8):1515-6. View

20.

Brater D, Anderson S, Baird B, Campbell W . Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men. Kidney Int. 1985; 27(1):66-73. DOI: 10.1038/ki.1985.11. View